Automatic injector: Current Opportunities and Future Growth Areas

Since the introduction of the automatic injector (autoinjectors) device in 1980s, their numerous benefits, such as ease-of-use, reduced chances of dosing errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries, have been widely recognized among consumers and healthcare service providers. Automatic injector are also considered to be potential life cycle management tool. Drugs nearing patent expiry can be developed for delivery using an automatic injector and retain market exclusivity as a combination product. Various initiatives are underway to make these devices even more patient-friendly; in fact, between January 2013 and December 2017, close to 3,800 patents have been published in this domain, indicating the rapid pace at which research is being carried out in this field.

The Market Landscape of Autoinjectors is Steadily Widening

Over 85 unique autoinjector devices and 75 drug-autoinjector combination products are currently available in the market.

The Interest is Validated by a Large Number of Recently Filed Patents

As a result of the widening research interest, close to 3,800 patents have been filed recently; automatic injector devices, with improved features, are gradually becoming mainstream

Various industry and non-industry players have filed over 3,800 patents focusing on autoinjectors reflecting there growing interest in this domain

Healthy Competition Among Stakeholders is Fostering Technological Advances

Ongoing innovation has led to the development of robust technology platforms that have significantly strengthened the growing product landscape in this domain.

The Development Focus is Spread Across a Variety of Target Therapeutic Areas

Several combination products are already approved for a diverse array of indications; majority of them are disposable in nature and designed for subcutaneous drug delivery

Close to 20% combination products are used for the treatment of patients suffering from Rheumatoid Arteritis / Psoriasis / Other Arthritis

Our Proprietary Analysis Reveals Several Drugs that are Suited for Delivery via Autoinjectors

A detailed evaluation of both marketed / pipeline products highlights several drug candidates that are suited for delivery via autoinjectors.

We Expect the Market to Steadily Evolve Over the Next Decade …

Overall, the global autoinjectors market is poised to grow at a steady pace in the mid-long term; the opportunity is likely to be well-distributed across different regions of the world

The overall autoinjectors market is fragmented across various segmentation including type of device, usability and geography. Further, US is expected to capture the highest share by 2030

… As Devices with New Features Get Commercialized for A Wider Pool of Indications

Rising incidence of chronic conditions is expected to drive future growth; devices offering subcutaneous drug delivery will continue to capture over 90% of the market’s share.

For more details, you can also download the SAMPLE REPORT on automatic injector by Roots Analysis.